Phenytoin Correction Calculator

Phenytoin circulates roughly 90 percent bound to plasma albumin, so a total serum concentration is only interpretable when binding is intact. The Winter-Tozer adjustment rescales the measured total to the value it would have shown at a reference albumin near 4.5 g/dL, the point at which the denominator 0.2 x albumin + 0.1 equals 1.0 and no correction occurs. Each 1 g/dL fall in albumin releases about a fifth of the normally bound drug into the free compartment, so a measured 7.2 mcg/mL at an albumin of 2.0 g/dL corrects to 14.4 mcg/mL - inside the usual 10 to 20 mcg/mL total target (about 40 to 79 micromol/L) rather than below it. The free reference range is 1 to 2 mcg/mL, and toxic signs track the free fraction: nystagmus above roughly 20 mcg/mL total, ataxia above 30, lethargy and encephalopathy above 40. The renal and dialysis variant substitutes a coefficient of 0.1 because retained uremic organic acids compete for the same albumin sites, pushing the free fraction from about 10 percent toward 20 to 25 percent even when albumin is normal. Because 0.1 x albumin + 0.1 never reaches 1.0 at physiologic albumin values, that form always inflates the reported number and should be applied only when creatinine clearance is genuinely low. The main limitations are that the coefficients are fixed population averages, that displacement by valproic acid, high-dose salicylates, or ceftriaxone is not modeled, and that the correction says nothing about phenytoin saturable Michaelis-Menten clearance. A directly measured free level by ultrafiltration remains the reference standard whenever it is available.

Phenytoin was first synthesized in 1908 by the German chemist Heinrich Biltz, who was studying diphenylhydantoin derivatives and had no interest in the nervous system. Its anticonvulsant activity was uncovered only in the late 1930s, when H. Houston Merritt and Tracy Putnam screened compounds in an electrically induced seizure model in cats and found that this one suppressed convulsions without the heavy sedation caused by phenobarbital. Parke-Davis marketed it as Dilantin in 1938, and it became the dominant drug for focal and generalized tonic-clonic seizures for decades. Reliable serum assays arrived with gas-liquid chromatography and later immunoassays in the 1960s and 1970s, which is when clinicians first documented the concentration thresholds at which nystagmus and ataxia appear. The albumin adjustment itself is credited to Michael E. Winter and Thomas N. Tozer, pharmacy faculty at the University of California, San Francisco, who published it in the reference text Applied Pharmacokinetics around 1980; the same relationship is often called the Sheiner-Tozer equation after related binding work by Lewis Sheiner. The lower uremic coefficient came out of binding studies in patients with renal failure and on dialysis showing markedly reduced albumin affinity. Later investigators questioned the original constants: in 1997 Anderson and colleagues proposed a revised coefficient near 0.25 for trauma and elderly patients with hypoalbuminemia, and subsequent validation work has generally found the classic form overestimates in some populations, which is why direct free assays have steadily replaced it where laboratories can support them.